en Health Technology Assessment Health Technology Assessment Original Research Original Research <p>&nbsp;&nbsp;<strong>&nbsp; Background: </strong>Hip, vertebral and wrist fractures are the most common consequences of osteoporosis. This study aimed at analyzing the cost-effectiveness of teriparatide (CinnoPar&reg;), compared with alendronate and risedronate, in the treatment of women aged 60 and over with postmenopausal osteoporosis in Iran.<br> <strong>&nbsp;&nbsp; Methods: </strong>A decision tree model with a 2-year time horizon was used to compare treatment with teriparatide (CinnoPar&reg;) with the following treatment strategies: two years of treatment with alendronate and two years of treatment with risedronate in women aged 60 years and over or those at risk of osteoporosis. Cost per QALY was calculated for 3 treatment strategies from the model. After base case analysis, one-way sensitivity analysis was performed on key parameters of the model to assess their impact on the study results and the cost-effectiveness of different treatment strategies and the model robustness. TreeAge Pro 2011 software was used for modeling and data analysis.<br> <strong>&nbsp;&nbsp; Results:</strong> Incremental cost-effectiveness ratio (ICER) of alendronate and teriparatide than risedronate (base treatment) were US$-2178.03 and US$483,783.67 per QALY, respectively. Therefore, the dominant and cost-effective treatment option was alendronate. In the one-way sensitivity analysis, the impact of annual 25% increase or decrease in the teriparatide cost on its ICER was remarkable. Also, reducing the discount rate from 0.03 to 0.0 had the greatest impact on the ICER of the teriparatide.<br> <strong>&nbsp;&nbsp; Conclusion:</strong> The treatment strategy of teriparatide is more expensive than risedronate and alendronate and is associated with very little increase in QALYs. A significant reduction in teriparatide price and a limit in its use only for high-risk women and for acute and short-term treatment courses can contribute to its cost-effectiveness.<br> &nbsp;</p> Osteoporosis, Cost-effectiveness, Teriparatide, Risedronate, Alendronate, Postmenopausal Women, Fracture, Iran 224 229 http://mjiri.iums.ac.ir/browse.php?a_code=A-10-3002-1&slc_lang=en&sid=1 Amir Ali Ebadi Fard Azar 200319475328460033908 200319475328460033908 No Medicine School, Iran University of Medical Sciences, Tehran, Iran. Aziz Rezapour rezapoor_a57@yahoo.com 200319475328460033909 200319475328460033909 No Health Management and Economics Research Center, Iran University of Medical Sciences, Tehran, Iran. Vahid Alipour vahid.alipour1360@yahoo.com 200319475328460033910 200319475328460033910 No Health Management and Economics Research Center, Iran University of Medical Sciences, Tehran, Iran. Ali Sarabi-Asiabar sarabi.a@iums.ac.ir 200319475328460033911 200319475328460033911 No Health Management and Economics Research Center, Iran University of Medical Sciences, Tehran, Iran. Serajaddin Gray seraj.1365@gmail.com 200319475328460033912 200319475328460033912 No Department of Health Management and Economics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran. Mohammadreza Mobinizadeh mr.mobini1986@gmail.com 200319475328460033913 200319475328460033913 No National Institute for Health Research, Tehran University of Medical Sciences, Tehran, Iran. Mani Yousefvand vbutterfly60@gmail.com 200319475328460033914 200319475328460033914 No Department of Health Management and Economics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran. Jalal Arabloo arabloo_j64@yahoo.com 200319475328460033915 200319475328460033915 Yes Health Management and Economics Research Center, Iran University of Medical Sciences, Tehran, Iran.